FDA’s Circulatory System Devices advisory panel will meet March 20 in Gaithersburg, Md., to review Abbott Vascular’ PMA for the MitraClip percutaneous mitral repair device.
Abbott is seeking an indication for the percutaneous reduction of significant symptomatic mitral regurgitation (MR≥3) in patients who would benefit from correction of mitral regurgitation but who have been deemed...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?